Core Viewpoint - Tianyi Medical (301097) shows a positive stock performance with a closing price of 57.98 yuan, up 2.17% on November 26, 2025, indicating a potential recovery in investor sentiment and market interest in the company [1]. Financial Performance - For the first three quarters of 2025, Tianyi Medical reported a main business revenue of 387 million yuan, a year-on-year increase of 24.14% [4]. - The net profit attributable to shareholders reached 20.09 million yuan, up 216.81% year-on-year, while the net profit excluding non-recurring items was 8.41 million yuan, increasing by 762.11% [4]. - In Q3 2025 alone, the company achieved a quarterly main business revenue of 160 million yuan, a 48.03% increase year-on-year, and a quarterly net profit of 10.61 million yuan, up 227.86% [4]. Market Position - Tianyi Medical's total market capitalization is 3.418 billion yuan, significantly lower than the industry average of 10.994 billion yuan, ranking 96 out of 124 in the medical device industry [4]. - The company's net assets stand at 1.182 billion yuan, with a net profit margin of 5.4%, which is below the industry average of 9.57% [4]. - The price-to-earnings ratio (P/E) is 127.57, compared to the industry average of 54.58, indicating a higher valuation relative to earnings [4]. Capital Flow - On November 26, 2025, the net inflow of main funds was 542,700 yuan, accounting for 0.74% of the total transaction amount, while retail investors experienced a net outflow of 2.9192 million yuan, representing 3.96% of the total [1]. - Over the past five days, the financing balance has decreased from 619.08 million yuan to 504.78 million yuan, indicating a trend of net repayments in financing activities [2].
天益医疗（301097）11月26日主力资金净买入54.27万元